Kiora Pharmaceuticals Inc   (KPRX)
Other Ticker:  
Price: $0.6550 $-0.02 -2.385%
Day's High: $0.69 Week Perf: -5.58 %
Day's Low: $ 0.63 30 Day Perf: 18.57 %
Volume (M): 201 52 Wk High: $ 5.25
Volume (M$): $ 131 52 Wk Avg: $1.26
Open: $0.67 52 Wk Low: $0.46

 Market Capitalization (Millions $) 5
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) -13
 Cash Flow (TTM) (Millions $) -3
 Capital Exp. (TTM) (Millions $) 0

Kiora Pharmaceuticals Inc
Kiora Pharmaceuticals Inc is a leading pharmaceutical company that is dedicated to discovering, developing, and commercializing innovative therapies to address significant unmet medical needs. They focus on areas such as oncology, neurology, and immunology, with an emphasis on precision medicine and personalized therapies. Kiora Pharmaceuticals specializes in the research and development of novel drug compounds, often leveraging advanced technologies and collaborations with academic institutions and other industry partners. Their goal is to improve patient outcomes and enhance quality of life through the advancement of therapeutic options.

   Company Address: 332 Encinitas Blvd. Encinitas 92024 CA
   Company Phone Number: 224-9600   Stock Exchange / Ticker: NASDAQ KPRX
   KPRX is expected to report next financial results on March 22, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Kiora Pharmaceuticals Inc

Headline: KPRX Witnesses Significant Deterioration in Corporate Conduct during Fiscal Q3 of 2023

Kiora Pharmaceuticals Inc is a small company in the Major Pharmaceutical Preparations industry that has recently published its financial results for the third quarter of 2023. Although the company has not yet announced its revenue, it did reveal that it had a operating loss of $-5.918568 million during this period. To better understand these results, it is important to compare them to the company's performance in the previous year. In the third quarter of 2022, Kiora Pharmaceuticals Inc had an operating loss of $-3.703035 million, indicating a significant increase in losses.
It is not uncommon for companies to experience ups and downs as they strive to establish a successful business model. The financial period ending on September 30, 2023, was particularly challenging for Kiora Pharmaceuticals Inc, as the net loss expanded to $-5.763 million. This suggests that the company may be facing some difficulties in generating profits and maintaining financial stability.

Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals Inc Faces Deterioration in Operating Performance and Struggles to Secure Revenue Streams During Challenging Earnings Season

Kiora Pharmaceuticals Inc: Shareholders Hope for Moderations Amidst Challenging Earnings Season
Shareholders of Kiora Pharmaceuticals Inc (KPRX) have not held high hopes for any major moderations in the company throughout the earnings season of April to June 30, 2023. However, they are paying very close attention to the company's operating shortfall, which stood at $-2.633012 million during the same period. This figure reflects a contraction from the second quarter of 2022, where the operating shortfall was recorded at $-2.402048 million.
Despite this improvement in the operating shortfall, market participants are still speculating whether Kiora Pharmaceuticals Inc will start to cite revenue, as the company is seeking different business strategies to secure steady revenue streams. It is crucial for the company to demonstrate a capability to generate revenue to instill confidence among shareholders and investors.

Kiora Pharmaceuticals Inc

Kiora Pharmaceuticals Inc makes strides towards profitability with improved ROI and reduced operating deficit

Kiora Pharmaceuticals Inc is a healthcare company that specializes in the development and commercialization of innovative medicines. Based on their financial results for the 12 months ending in the first quarter of 2023, Kiora Pharmaceuticals Inc recorded a cumulative net loss of $-12 million, resulting in a negative return on investment (ROI) of -87.99%. This puts them below the industry average in terms of ROI, with 345 other companies within the healthcare sector having a higher ROI.
However, there is some good news for Kiora Pharmaceuticals Inc. Their ROI ranking has improved from the fourth quarter of 2022, where they were ranked at 4763, to 2228 in the first quarter of 2023. This shows that the company is making progress towards profitability and financial stability.



About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com